As of 2024-09-14, the EV/EBITDA ratio of Fate Therapeutics Inc (FATE) is -2.40. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FATE's latest enterprise value is 420.88 mil USD. FATE's TTM EBITDA according to its financial statements is -175.23 mil USD. Dividing these 2 quantities gives us the above FATE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 17.8x - 27.7x | 23.2x |
| Forward P/E multiples | 23.4x - 29.4x | 25.5x |
| Fair Price | (35.71) - (42.33) | (37.14) |
| Upside | -988.4% - -1152.9% | -1024.0% |
| Date | EV/EBITDA |
| 2024-09-13 | -2.40 |
| 2024-09-12 | -2.22 |
| 2024-09-11 | -2.31 |
| 2024-09-10 | -2.27 |
| 2024-09-09 | -2.03 |
| 2024-09-06 | -1.99 |
| 2024-09-05 | -2.10 |
| 2024-09-04 | -2.08 |
| 2024-09-03 | -2.03 |
| 2024-08-30 | -2.17 |
| 2024-08-29 | -2.09 |
| 2024-08-28 | -2.07 |
| 2024-08-27 | -2.12 |
| 2024-08-26 | -2.31 |
| 2024-08-23 | -2.28 |
| 2024-08-22 | -2.24 |
| 2024-08-21 | -2.33 |
| 2024-08-20 | -2.17 |
| 2024-08-19 | -2.15 |
| 2024-08-16 | -2.00 |
| 2024-08-15 | -1.99 |
| 2024-08-14 | -1.91 |
| 2024-08-13 | -1.96 |
| 2024-08-12 | -1.95 |
| 2024-08-09 | -1.98 |
| 2024-08-08 | -2.14 |
| 2024-08-07 | -2.38 |
| 2024-08-06 | -2.58 |
| 2024-08-05 | -2.51 |
| 2024-08-02 | -2.80 |
| 2024-08-01 | -2.96 |
| 2024-07-31 | -3.25 |
| 2024-07-30 | -3.12 |
| 2024-07-29 | -3.31 |
| 2024-07-26 | -3.32 |
| 2024-07-25 | -3.30 |
| 2024-07-24 | -3.16 |
| 2024-07-23 | -3.41 |
| 2024-07-22 | -2.75 |
| 2024-07-19 | -2.56 |
| 2024-07-18 | -2.59 |
| 2024-07-17 | -2.69 |
| 2024-07-16 | -2.75 |
| 2024-07-15 | -2.32 |
| 2024-07-12 | -2.14 |
| 2024-07-11 | -2.00 |
| 2024-07-10 | -1.82 |
| 2024-07-09 | -1.82 |
| 2024-07-08 | -1.82 |
| 2024-07-05 | -1.85 |